Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 43, Issue 6, 1997, Pages 661-664

  Martin, D E ^a   Tompson, D ^b,c   Boike, S C ^a   Tenero, D ^b,c   Ilson, B ^a   Citerone, D ^b,c   Jorkasky, D K ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c The Frythe   (United Kingdom)

Author keywords

Angiotensin II; Digoxin; Drug interaction; Eprosartan; Pharmacokinetics; Receptor antagonist

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIGOXIN; EPROSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030874256     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00608.x     Document Type: Article

References (12)

1. Duncia JV, Chiu AT, Carini, et al. The discovery of potent non-peptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chent 1990; 33: 1312-1329.
2. Weinstock J, Keenan RM, Samanen J, et al. 1-(carboxybenzyl)imidaxole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991; 34: 1514-1517.
3. Edwards RM, Aiyar N, Ohlstein EH, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175-181.
4. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR, Edwards RM, Gellai M. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Arch Pharmacol 1992; 345: 673-678.
5. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 227-244.
6. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol 1985; 5(Suppl A): 82A-90A.
7. Evans WE, Schentag JJ, Jusko WJ. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver: Applied Therapeutics, Inc., 1992.
8. Antman EM, Arnold JMO, Friedman PL, Smith TW. Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology. Cardio Drugs Ther 1987; 1: 183-189.
9. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
10. SAS/STAT User's Guide. Version 6, 4th ed., SAS Institute, Inc., Cary, North Carolina, 1989.
11. Hauschke D, Steinijans VW, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-78.
12. Bois FY, Tozer TN, Hauck WW, Chen M-L, Patnaik R, Williams RL. Bioequivalence: performance of several measures of extent of absorption. Pharm Res 1994; 11: 715-722.